1. Home
  2. GO vs ARVN Comparison

GO vs ARVN Comparison

Compare GO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

HOLD

Current Price

$9.30

Market Cap

732.0M

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.67

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GO
ARVN
Founded
1946
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
732.0M
658.2M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
GO
ARVN
Price
$9.30
$7.67
Analyst Decision
Hold
Buy
Analyst Count
10
19
Target Price
$11.30
$15.05
AVG Volume (30 Days)
2.6M
649.0K
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
$4,688,759,000.00
$262,600,000.00
Revenue This Year
$2.48
N/A
Revenue Next Year
$3.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.26
N/A
52 Week Low
$5.66
$6.06
52 Week High
$19.41
$14.22

Technical Indicators

Market Signals
Indicator
GO
ARVN
Relative Strength Index (RSI) 60.10 38.70
Support Level $9.01 $7.35
Resistance Level $9.44 $10.18
Average True Range (ATR) 0.44 0.43
MACD 0.06 0.08
Stochastic Oscillator 62.82 33.10

Price Performance

Historical Comparison
GO
ARVN

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: